Na-Ri Oh

Na-Ri Oh is a seasoned pharmaceutical executive with extensive experience in commercial product strategy, particularly in the fields of Hepatitis B and D, as well as Non-Alcoholic Steatohepatitis (NASH). Currently serving as the Global Head of HBV and HDV Commercial Product Strategy at Gilead Sciences, Na-Ri Oh leads global launches and marketing strategies for innovative treatments, including Hepcludex. Previous roles at Gilead include strategic leadership in access operations and marketing across several regions, as well as pivotal positions focused on HBV products. Prior to joining Gilead, Na-Ri Oh garnered experience at Boehringer Ingelheim Pharmaceuticals and practiced medicine in HIV at the University Hospital Frankfurt am Main. Na-Ri Oh holds an M.D. from Heidelberg University and a B.Sc. in Biochemistry and Molecular Biology from the University of Hamburg.